Dr. Kyaw Zin Thein, MD, is a highly skilled Medical Oncologist and Hematologist currently practicing at the Central Valley Treatment Center – Twain, affiliated with the Comprehensive Cancer Centers of Nevada. He also serves as a Clinical Assistant Professor at Touro University Nevada (TUN) and the University of Nevada, Las Vegas (UNLV). His dedication to patient care, research, and education has solidified his reputation as a leader in precision oncology and hematology.

Profile

Scopus

Google scholar

Orcid

Strengths for the Awards

• Impressive Academic and Clinical Training
  • Dr. Kyaw Zin Thein has a robust academic background, including advanced fellowships in hematology, oncology, and investigational cancer therapeutics at world-renowned institutions such as MD Anderson Cancer Center.
  • A double board-certified oncologist and hematologist with certifications valid through 2029, showcasing his extensive expertise and commitment to maintaining professional standards.
• Research Contributions and Publications
  • Author of 53 peer-reviewed journal articles, demonstrating significant contributions to advancing knowledge in oncology and hematology.
  • Published book chapters on cutting-edge topics like poly (ADP-ribose) polymerase inhibitors and multidisciplinary paradigms for head and neck cancer, reflecting his thought leadership in the field.
• Teaching and Mentorship
  • Active roles as Clinical Assistant Professor at UNLV and Touro University Nevada, contributing to medical education.
  • Mentorship of numerous trainees, ranging from medical students to fellows, highlighting his commitment to shaping the next generation of oncologists and researchers.
• Leadership and Awards
  • Held leadership roles, including Chief Fellow, Chief Resident, and committee member positions at esteemed institutions.
  • Recipient of multiple awards, such as the ASH Abstract Achievement Award and Research Recognition Awards, underscoring his excellence in research and clinical practice.

Education 🎓

Dr. Thein completed his M.B., B.S. (Doctor of Medicine) at the Institute of Medicine 1, Yangon, Myanmar (2004–2010). His advanced training includes:

• Residency in Internal Medicine at Kingsbrook Jewish Medical Center, NY (2012–2015).
• Fellowship in Hematology & Medical Oncology at Texas Tech University Health Sciences Center, TX (2016–2019).
• Advanced Fellowships in Investigational Cancer Therapeutics and Oncologic Emergency Medicine at the University of Texas MD Anderson Cancer Center (2015–2020).

Professional Experience 💼

Dr. Thein has held numerous prestigious positions:

• Medical Oncologist/Hematologist, Central Valley Treatment Center, Nevada (2023–present).
• Assistant Professor of Medicine, Division of Hematology and Medical Oncology, Oregon Health & Science University (OHSU) (2020–2023).
• Chief Fellow, Texas Tech University Health Sciences Center (2018–2019).
• Member of multiple professional committees, including the Knight Cancer Institute’s Data and Safety Monitoring Committee.

Research Interests On Health Sciences🔬

Dr. Thein’s research focuses on precision oncology, investigational cancer therapeutics, and immunotherapy. He has contributed extensively to advancing cancer care through his work on targeted therapies, combination regimens, and innovative diagnostic methods.

Awards & Recognitions 🏆

Dr. Thein has received numerous accolades, including:

• ASH Abstract Achievement Award, American Society of Hematology (2016).
• Research Recognition Awards from Kingsbrook Jewish Medical Center (2014, 2015).
• Excellence in Education Award, Myanmar American Medical Education Society (2011).

Publications 📚

• Copper deficiency anemia
  • Authors: ZW Myint, TH Oo, KZ Thein, AM Tun, H Saeed
  • Year: 2018
  • Citations: 298
• 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy
  • Authors: G Han, G Yang, D Hao, Y Lu, K Thein, BS Simpson, J Chen, R Sun, et al.
  • Year: 2021
  • Citations: 136
• Precision therapy for RET-altered cancers with RET inhibitors
  • Authors: KZ Thein, V Velcheti, BHM Mooers, J Wu, V Subbiah
  • Year: 2021
  • Citations: 112
• Adverse effects of immune checkpoint therapy in cancer patients visiting the emergency department of a comprehensive cancer center
  • Authors: I El Majzoub, A Qdaisat, KZ Thein, MA Win, MM Han, K Jacobson, et al.
  • Year: 2019
  • Citations: 91
• Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism
  • Authors: MA Win, KZ Thein, A Qdaisat, SCJ Yeung
  • Year: 2017
  • Citations: 83
• The contemporary management of cancers of the sinonasal tract in adults
  • Authors: R Thawani, MS Kim, A Arastu, Z Feng, MT West, NF Taflin, KZ Thein, R Li, et al.
  • Year: 2023
  • Citations: 74
• Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers
  • Authors: B Garmezy, J Gheeya, HY Lin, Y Huang, T Kim, X Jiang, KZ Thein, et al.
  • Year: 2022
  • Citations: 74
• Therapeutics targeting mutant KRAS
  • Authors: KZ Thein, AB Biter, DS Hong
  • Year: 2021
  • Citations: 55
• Pernicious anemia: Pathophysiology and diagnostic difficulties
  • Authors: TW Htut, KZ Thein, TH Oo
  • Year: 2021
  • Citations: 52
• Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy
  • Authors: KZ Thein, TW Htut, S Ball, S Swarup, A Sultan, TH Oo
  • Year: 2020
  • Citations: 45

Conclusion 🌟

Dr. Kyaw Zin Thein is a visionary leader in oncology and hematology, with a career distinguished by cutting-edge research, impactful teaching, and exceptional clinical care. His dedication to advancing cancer therapies and mentoring future medical professionals underscores his commitment to transforming cancer treatment and education worldwide.